European study of COVID-19 vaccine effectiveness against hospitalised SARI patients laboratory-confirmed with SARS-CoV-2 (I-MOVE-COVID VE hospital study)

Study identification

• EU PAS number:
  EUPAS39683
• Study ID:
  39684
• Official title and acronym:
  European study of COVID-19 vaccine effectiveness against hospitalised SARI patients laboratory-confirmed with SARS-CoV-2 (I-MOVE-COVID VE hospital study)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Belgium

  France

  Germany

  Italy

  Netherlands

  Norway

  Portugal

  Spain

  Switzerland

  United Kingdom
• Study description:
  Multicentre European study at hospital level, measuring vaccine effectiveness using a test-negative design. Participating hospitals recruit Severe Acute Respiratory Infection patients: those testing positive for SARS-CoV-2 are cases and those testing negative are the controls
• Study status:
  Planned

Research institutions and networks

Institutions

EpiConcept

Study timelines

Date when funding contract was signed

Planned: 15/03/2020

Study start date

Planned: 01/02/2021

Date of final study report

Planned: 01/03/2022

Sources of funding

EU institutional research programme

Other

More details on funding

European Commission, Public Health Institutes

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

https://www.imoveflu.org/wp-content/uploads/2021/02/08feb2021_draft_generic_VE_protocol_hospital-based_COVID-19_v07.pdf,,DOI: 10.5281/zenodo.4555315